Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
BCL2 inhibitors
CD33 inhibitors
FLT3 inhibitors
IDH inhibitors
acute myeloid leukemia
anthracyclines
cytarabine
hypomethylating agents
pharmacogenetics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
03 Mar 2022
03 Mar 2022
Historique:
received:
21
01
2022
revised:
16
02
2022
accepted:
28
02
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration.
Identifiants
pubmed: 35335935
pii: pharmaceutics14030559
doi: 10.3390/pharmaceutics14030559
pmc: PMC8954545
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : CD21/00022
Organisme : Instituto de Salud Carlos III
ID : IMPaCT, IMP/00009
Références
Pharmacogenet Genomics. 2014 Sep;24(9):436-41
pubmed: 25000516
Pharmacogenomics J. 2016 Nov;16(6):530-535
pubmed: 26345518
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Leukemia. 2021 Jun;35(6):1571-1585
pubmed: 33077867
Adv Exp Med Biol. 1999;457:571-7
pubmed: 10500836
Cancer Causes Control. 2008 May;19(4):379-90
pubmed: 18064533
Clin Pharmacol Ther. 2016 Jun;99(6):651-60
pubmed: 26663398
Pharmacogenomics J. 2018 Apr;18(2):301-307
pubmed: 28485375
J Hum Genet. 2013 Jun;58(6):353-61
pubmed: 23677058
Blood Cancer J. 2019 May 21;9(6):51
pubmed: 31113932
Pac Symp Biocomput. 2022;27:385-396
pubmed: 34890165
Pharmacogenet Genomics. 2015 Jun;25(6):317-21
pubmed: 25850965
Blood. 2020 Feb 13;135(7):463-471
pubmed: 31841594
Syst Rev. 2019 May 3;8(1):109
pubmed: 31053175
Cancer Res. 2002 Sep 1;62(17):4955-62
pubmed: 12208746
Nat Med. 2015 Feb;21(2):178-84
pubmed: 25599133
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Blood. 2007 May 15;109(10):4168-70
pubmed: 17227830
Pediatr Clin North Am. 2008 Feb;55(1):21-51, ix
pubmed: 18242314
Pharmacogenomics J. 2018 May 22;18(3):444-449
pubmed: 29205204
Hum Genet. 2006 Apr;119(3):276-83
pubmed: 16446974
Leuk Lymphoma. 2021 Mar;62(3):659-668
pubmed: 33135528
Cancer Epidemiol. 2014 Dec;38(6):728-32
pubmed: 25246379
Chin Med J (Engl). 2012 Jun;125(12):2137-43
pubmed: 22884143
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2118-20
pubmed: 23001242
Clin Cancer Res. 2006 Mar 15;12(6):1794-803
pubmed: 16551864
Int J Mol Sci. 2020 Aug 06;21(16):
pubmed: 32781546
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
pubmed: 10716719
Pharmacogenomics. 2016 Jul;17(11):1245-1272
pubmed: 27381050
Pharmacogenomics J. 2015 Apr;15(2):109-18
pubmed: 25558979
Curr Opin Genet Dev. 2016 Feb;36:100-6
pubmed: 27162099
Pharmacogenet Genomics. 2006 May;16(5):315-20
pubmed: 16609362
Cancer Chemother Pharmacol. 2016 Sep;78(3):533-40
pubmed: 27422302
Pharmacogenet Genomics. 2009 Aug;19(8):567-76
pubmed: 19623099
Pharmacogenomics. 2016 Sep;17(14):1519-31
pubmed: 27548009
Clin Pharmacol Ther. 2001 Aug;70(2):189-99
pubmed: 11503014
Lancet. 2018 Aug 18;392(10147):593-606
pubmed: 30078459
J Pharmacol Exp Ther. 2011 Oct;339(1):9-23
pubmed: 21712425
J Clin Oncol. 2016 Mar 1;34(7):747-55
pubmed: 26786921
Leuk Res. 2002 Jul;26(7):621-9
pubmed: 12008078
Biomedicines. 2020 Apr 22;8(4):
pubmed: 32331352
Adv Ther. 2018 Nov;35(11):2015-2023
pubmed: 30264382
Br J Haematol. 2014 Dec;167(5):671-80
pubmed: 25155901
Drug Metab Dispos. 2005 Feb;33(2):254-7
pubmed: 15537833
Crit Rev Oncol Hematol. 2021 Apr;160:103281
pubmed: 33667660
Leuk Res. 2008 Oct;32(10):1601-4
pubmed: 18272218
Leukemia. 2009 Oct;23(10):1929-32
pubmed: 19458626
Clin Pharmacol Ther. 2006 Nov;80(5):427-39
pubmed: 17112800
Leuk Lymphoma. 2018 Feb;59(2):274-287
pubmed: 28573892
Pharmacogenetics. 2003 Jan;13(1):29-38
pubmed: 12544510
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Pharmacogenomics J. 2013 Aug;13(4):335-41
pubmed: 22584460
Pharmacol Rev. 2011 Mar;63(1):157-81
pubmed: 21245207
Cancer Lett. 2019 Mar 31;445:34-44
pubmed: 30639533
Blood Adv. 2022 Feb 22;6(4):1278-1295
pubmed: 34794172
Clin Exp Pharmacol Physiol. 2014 Jun;41(6):400-7
pubmed: 24684492
Clin Cancer Res. 2013 Mar 15;19(6):1620-7
pubmed: 23444229
J Clin Oncol. 2010 Jan 1;28(1):160-5
pubmed: 19933910
Biomed Res Int. 2015;2015:309491
pubmed: 26090398
J Clin Oncol. 2012 May 1;30(13):1422-8
pubmed: 21900104
Int J Mol Epidemiol Genet. 2010;1(3):201-7
pubmed: 21311724
Br J Clin Pharmacol. 2017 Apr;83(4):846-854
pubmed: 27859472
Circulation. 2005 Dec 13;112(24):3754-62
pubmed: 16330681
Eur J Cancer. 2013 Jan;49(2):403-10
pubmed: 22964418
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Pharmacogenomics J. 2012 Apr;12(2):111-8
pubmed: 20938465
Haematologica. 2005 Dec;90(12):1699-701
pubmed: 16330448
Blood Rev. 2020 Nov;44:100675
pubmed: 32147087
Front Genet. 2013 Nov 11;4:231
pubmed: 24273552
Pharmacogenomics. 2012 Jul;13(9):1009-21
pubmed: 22838949
Expert Rev Hematol. 2017 Oct;10(10):863-874
pubmed: 28799432
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Drug Metab Dispos. 2013 Mar;41(3):541-5
pubmed: 23230131
Expert Rev Hematol. 2020 Oct;13(10):1057-1065
pubmed: 32869672
Br J Haematol. 2002 Jun;117(4):860-8
pubmed: 12060121
J Cancer Res Clin Oncol. 2012 Jun;138(6):959-69
pubmed: 22358301
Pharmacogenomics. 2013 Sep;14(12):1449-66
pubmed: 24024897
Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485
pubmed: 29723928
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Mol Pharmacol. 2017 Jan;91(1):14-24
pubmed: 27777271
J Clin Pharmacol. 2016 Nov;56(11):1335-1343
pubmed: 26953185
Front Pharmacol. 2015 Feb 10;6:13
pubmed: 25713533
Sci Transl Med. 2015 Apr 1;7(281):281re2
pubmed: 25834112
Curr Drug Metab. 2010 Jan;11(1):115-28
pubmed: 20302569
Br J Haematol. 1998 Dec;103(4):1096-103
pubmed: 9886326
Ann Hematol. 2020 Jul;99(7):1429-1440
pubmed: 32514626
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Cancers (Basel). 2021 Nov 12;13(22):
pubmed: 34830832
Int J Cancer. 2006 May 1;118(9):2195-201
pubmed: 16331627
Nature. 2018 Jul;559(7712):125-129
pubmed: 29950729
JCO Precis Oncol. 2019 May 23;3:
pubmed: 32914031
Pharmacogenetics. 2004 Nov;14(11):759-68
pubmed: 15564883
Eur J Pharmacol. 2021 Mar 15;895:173894
pubmed: 33476656
Curr Drug Metab. 2018;19(1):55-74
pubmed: 29090664
Pharmacogenomics. 2012 Aug;13(11):1257-69
pubmed: 22920396
Pharmacogenomics. 2012 Feb;13(3):269-82
pubmed: 22304580
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Leuk Lymphoma. 2017 Dec;58(12):2880-2894
pubmed: 28573946
Eur J Clin Pharmacol. 2015 Mar;71(3):293-302
pubmed: 25567217
Pharmacogenomics. 2015 Nov;16(17):1907-12
pubmed: 26556583
J Mol Diagn. 2015 Nov;17(6):661-8
pubmed: 26331834
J Exp Clin Cancer Res. 2014 Nov 15;33:90
pubmed: 25398670
Oncol Rev. 2012 Apr 17;6(1):e8
pubmed: 25992210